Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Host factors determining the efficacy of hepatitis C treatment.

Journal of gastroenterology - 1 Jan 2013

Chuang Wan-Long, Yu Ming-Lung

Abstract excerpt

Combination therapy with pegylated interferon and ribavirin is the standard of care (SOC) for the treatment of chronic hepatitis C (CHC). Treating CHC with SOC may show a sustained virological response (SVR) in approximately 50-70 % of genotype 1 CHC patients and an SVR in 70-90 % of genotype 2 CHC patients. The genotype, baseline viral load, and viral kinetics (i.e., rapid virologic response and early virologic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to DNA-Directed RNA Polymerases
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Insulin Resistance

Share to Interferons

Share to Interleukins

Share to Protease Inhibitors

Share to Viral Nonstructural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 23104468
DOI: 10.1007/s00535-012-0669-x
PMCID: PMC3698435

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Host factors determining the efficacy of hepatitis C treatment.PMID 23104468Read ↗

Role of viral and host factors in interferon based therapy of hepatitis C virus infection.Semantic proximity Read ↗

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsSemantic proximity Read ↗

Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.Semantic proximity Read ↗

Analysis of Host and Viral-Related Factors Associated to Direct Acting Antiviral Response in Hepatitis C Virus Patients.Semantic proximity Read ↗

Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.Semantic proximity Read ↗

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C.Semantic proximity Read ↗

Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin.Semantic proximity Read ↗

Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.Semantic proximity Read ↗

Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?Semantic proximity Read ↗

Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.Semantic proximity Read ↗

Pharmacogenetics of hepatitis CSemantic proximity Read ↗

Factors influencing hepatitis C cure in the era of direct-acting antivirals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.